Hiring – Part-time Operations Associate/Executive Assistant
Part-time Operations Associate/Executive AssistantYuhan USA CorporationWork locations: Cambridge, MAEmployee type: part-timeContact Information: yjlee@yuhan-usa.com Yuhan USA Corporation was established in January 2018 as a wholly owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 99-year heritage. As an outpost of Yuhan’s globalization strategy, Yuhan USA is searching for business development and collaboration opportunities in […]
Yuhan Presents Phase 1b Part 2 Results for Lesigercept – Shows Efficacy in Omalizumab-Refractory Patients
Date: 6/13/25 Yuhan Corporation presented positive Phase 1b Part 2 results for its investigational anti-IgE biologic Lesigercept (YH35324) at the EAACI 2025 Annual Meeting in Glasgow. Lesigercept is a novel Fc-fusion protein that binds to both circulating free IgE and FcεRIα autoantibodies, offering a dual mechanism to alleviate allergic symptoms. The study focused on 9 […]
Yuhan Corporation Receives $15 Million Milestone from Janssen for Launch of Lazertinib + Amivantamab Combination Therapy in Japan
Yuhan Corporation announced that it will receive a milestone payment of $15 million (approximately 20.7 billion KRW) from Janssen Biotech, a subsidiary of the multinational pharmaceutical company Johnson & Johnson. The milestone amount is expected to be received within 60 days. This milestone was triggered by the commercialization of Yuhan’s “Lazertinib” (brand name Leclaza in […]
Yuhan Presents Preclinical Data on Targeted Therapy YH42946 and Bispecific Immunotherapy YH32364
At the AACR 2025 Annual Meeting, Yuhan Corporation unveiled promising preclinical results for two of its cancer drug candidates: YH42946, a HER2/EGFR tyrosine kinase inhibitor (TKI), and YH32364, an EGFR×4-1BB bispecific antibody co-developed with ABL Bio. YH42946, licensed from J INTS BIO in 2023, targets tumors with HER2 and EGFR exon 20 insertions, mutations often […]
Yuhan’s HER2×4-1BB Bispecific Antibody YH32367 Shows Early Efficacy and Safety in Phase 1 Solid Tumor Trial
At the AACR 2025 Annual Meeting, Yuhan Corporation presented encouraging interim results from a Phase 1 trial of YH32367, a bispecific antibody targeting HER2 and 4-1BB, in patients with HER2-positive solid tumors refractory or resistant to trastuzumab (Herceptin). The study showed an objective response rate (ORR) of 22.6% and a disease control rate (DCR) of […]
Lazertinib + Amivantamab Combo from J&J Posts Strong Q1 Sales, Strengthening Its Position in NSCLC Treatment
Johnson & Johnson (J&J) reported that the combination therapy of Lazertinib (brand name Leclaza in Korea) and Amivantamab (brand name Rybrevant) achieved impressive global sales of $141 million (approx. 200 billion KRW) in Q1 2025. Of this, $113 million (approx. 161 billion KRW) was from the U.S. market alone, accounting for 80% of total revenue. […]
유한양행 한국 본사 중앙 연구소에서 경력사원을 채용하고자 합니다.
채용일정, 지원 자격 등의 정보는 링크를 확인해 주시기 바랍니다. #hiring
RYBREVANT® plus LAZCLUZE™ shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
J&J는 EGFRxMET 이중항체 ‘아미반타맙 (제품명 리브리반트)’와 유한양행이 개발해 J&J에 라이선스아웃한 3세대 EGFR TKI ‘레이저티닙 (제품명 라즈클루즈)’가 타크리소 대비 환자의 OS를 통계적으로, 임상적으로 유의미하게 개선했다고 밝힘. Johnson & Johnson has announced that its chemotherapy-free combination of Rybrevant® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib) has demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to […]
European Commission approves RYBREVANT® in combination with LAZCLUZE® for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
유럽연합 집행위원회는 EGFR 변이 진행성 비소세포폐암 환자의 1차 치료제로 J&J의 RYBREVANT®(amivantamab)와 유한양행이 개발해 J&J에 라이선스아웃한LAZCLUZE®(lazertinib)와의 병용 요법을 승인함. The European Commission has approved the combination of RYBREVANT® (amivantamab) and LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or L858R substitution mutations. This […]
RYBREVANT® plus LAZCLUZE™ by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. LAZCLUZE™ is anti-cancer drug developed by Yuhan Corporation licensed out to Janssen Biotech in 2018.
Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved […]